Navigation Links
Device That Targets Brain Cancer Shows Promising Results

Early data for an investigational device that specifically targets rapidly growing cancer cells with intermediate frequency electrical fields , called Tumor-Treating Fields (TTFields), has found that it more than doubled the median overall survival rates in patients with the most common and aggressive type of malignant brain tumor.

The device, called the Novo-TTF, uses electrical fields to disrupt tumor growth by interfering with cell division of cancerous cells, causing them to stop proliferating and die off instead of dividing and growing.

Healthy brain cells rarely divide and have different electrical properties than cancerous brain cells. This allows the device to target cancer cells without affecting the healthy cells.

The 10 patients who were being treated with the device were suffering from recurrent glioblastoma multiforme (GBM), the most common and aggressive type of malignant brain tumor.

Researchers found that among the patients treated with the Novo-TTF, the median length of time to disease progression was 26.1 weeks; progression free survival at six months was 50 percent; and median overall survival was 62.2 weeks.

This is more than double the rates reported in historical data approximately 9.5 weeks, 15.3 percent, and 29.3 weeks, respectively.

"The novel mechanism of action of the Novo-TTF relies on the physical properties of the cancer cells, their shape and size, rather than the chemical make-up. We believe that this distinction enables the device to stop local proliferation and metastasis of cancer, which would explain the efficacy observed in these early findings," said Dr. Elion Kirson lead author and Vice President of Research and Development, NovoCure.

"Based on our preliminary research, we believe that there is a high probability that TTFields may prove to be an effective and safe approach to treating a large number of human cancers," Dr Kirson a dded.

This research, which includes the results of cell culture, animal and early phase human trials, appears in the current issue of the Proceedings of the National Academy of Sciences (PNAS).


'"/>




Related medicine news :

1. Injection supports Heart Devices
2. New Heart-Screening Device ,An Accurate Predictor Of Heart Disease
3. Government Organisation Proposes Strict Guidelines For SubStandard Medical Devices
4. Withdrawal Notice Issued For Older Pacemakers Due To Malfunctioning of the Device
5. New Implantable Device That Can Keep The Heart Ticking
6. Making MRIs Safe for Patients With Implantable Heart Devices
7. Researchers Develop Device For Detecting Atherosclerotic Plaques
8. A Cheap Device to Stop Snoring from New Zealand
9. Scientists Concerned Over Increasing Malfunction Of Heart Devices
10. Device For Improving Bone Mass In Osteoporosis
11. Anti-Microbial Coating For Use Over Biomedical Devices Developed
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
Breaking Medicine Technology: